Cannabis and Alzheimer’s: What Researchers Are Learning
Alzheimer’s disease(opens in new tab) affects far more than memory. As the disease progresses, people living with Alzheimer’s and other forms of dementia may experience changes in mood, behavior, sleep and communication. Agitation can also become a significant concern, particularly during later stages of the disease. As cannabis research continues to evolve, scientists are studying cannabinoids like THC and CBD to better understand their potential clinical applications.
That doesn’t mean cannabis is a treatment for Alzheimer’s. It isn’t.
Cannabis has not been approved by the FDA to treat Alzheimer’s disease, and current evidence has not established commercially available cannabis as a way to prevent, cure or reverse it. But researchers are asking some interesting questions and learning more.
Why Are Researchers Studying Cannabinoids?
Cannabis contains numerous naturally occurring compounds known as cannabinoids, including THC and CBD. Researchers continue to study how these compounds interact with the human body, including the endocannabinoid system, and whether specific cannabinoid formulations may warrant further clinical study.
One area receiving attention is agitation associated with dementia.
Agitation can include restlessness, repetitive behaviors, verbal outbursts, physical aggression and other expressions of distress. These symptoms can be especially challenging for people living with dementia and those caring for them. Researchers have been studying whether specifically formulated cannabinoid based medications could have potential applications in this area. And some recent findings have added to that conversation.
A Recent Study of THC, CBD and Dementia
In July 2026, researchers presented results from the Phase 2 LiBBY clinical trial at the Alzheimer’s Association International Conference.
The study included 120 people with Alzheimer’s disease or other forms of dementia who were eligible for or receiving hospice care and experiencing clinically significant agitation. Researchers compared a specific investigational oral formulation containing THC and CBD with a placebo over 12 weeks.
According to the results presented, participants receiving the investigational formulation had a statistically significant greater reduction in measured agitation scores compared with the placebo group. Researchers also reported differences between the groups in clinician rated overall improvement.
While those findings are noteworthy.. context matters. The trial involved a specific investigational formulation, specific dosages and a specific population of people with late stage dementia. It does not establish that commercially available cannabis products will produce the same results.
This distinction is important.
Research Is Not the Same as Treatment
The FDA has not approved cannabis itself for the treatment of Alzheimer’s disease or any other disease or condition. Current evidence also does not establish commercially available cannabis as a way to cure Alzheimer’s, reverse dementia, restore lost memory, prevent the disease or stop its progression.
The FDA has approved certain prescription medications derived from or related to cannabinoids for specific medical conditions. Those medications have gone through the FDA drug approval process and should not be confused with cannabis products available at dispensaries.
Likewise, findings involving a controlled investigational THC and CBD formulation cannot automatically be applied to flower, edibles, vapes, concentrates or other cannabis products. When it comes to science, the details matter.
So, Why Does This Research Matter?
Because there is still a lot to learn about cannabis and the human body. Studies like LiBBY(opens in new tab) allow researchers to ask much more specific questions about cannabinoids. How do different cannabinoids interact with the body? What happens at different concentrations? How do age, medications and existing health conditions affect those interactions? Which formulations deserve additional study?
Controlled clinical research helps scientists separate what looks promising from what can actually be demonstrated. And that’s an important distinction in an industry where hype can sometimes move faster than the science.
Cannabis, Older Adults and Safety
Cannabis and cannabinoids affect people differently, and older adults may have additional considerations. Age, medical conditions and prescription medications can all influence how someone responds to THC, CBD or other cannabinoids. Cannabinoids can also cause side effects and may interact with medications.
Anyone considering cannabis or cannabinoid products in connection with Alzheimer’s, dementia or another medical condition should always first speak with a physician or qualified healthcare professional. Cannabis should never replace an FDA approved medication or established treatment plan without professional medical guidance.
Keep Following the Science
At Nuthera(opens in new tab), we think responsible cannabis education means being upfront about what we know, what we don’t, and what researchers are still figuring out.
Research involving cannabinoids and dementia is worth watching. Recent and current clinical studies are adding new information to the conversation, and future research may give us a much clearer understanding of the potential role of specific cannabinoids and cannabinoid based medications.
For now, the distinction is simple:
Cannabinoids are being studied in connection with Alzheimer’s and dementia. Cannabis itself is not an FDA approved treatment for Alzheimer’s disease. But, there’s always hope for a better, more natural way of battling this unfortunate disease.
Medical and Education Disclaimer:
This article is for general educational and informational purposes only and is not medical advice. It should not be interpreted as a recommendation to use cannabis or any cannabis product to diagnose, treat, cure, mitigate or prevent Alzheimer’s disease, dementia or any other medical condition.
Cannabis and cannabinoids may cause side effects and interact with medications. Consult a physician or qualified healthcare professional regarding medical conditions, medications and treatment decisions.
Nuthera products are not intended to diagnose, treat, cure or prevent any disease.